瑞舒伐他汀联合阿仑膦酸钠治疗甲状腺功能亢进继发骨质疏松患者骨密度和血清学指标的研究
|
摘要
目的研究探讨瑞舒伐他汀联合阿仑膦酸钠治疗甲状腺功能亢进继发骨质疏松的临床疗效及对患者骨密度、血清学指标的影响。方法方便选择2016年1月—2018年1月在该院进行治疗的80例甲状腺功能亢进继发骨质疏松患者进行研究,按随机分配原则分为观察组和对照组,各40例。对照组给予阿仑膦酸钠治疗,观察组患者在此基础上加用瑞舒伐他汀治疗。连续治疗3个月后对两组患者的临床疗效、甲状腺功能指标、骨密度和血清学指标以及不良反应发生率进行评价比较。结果①观察组总有效率95.00%(38/40),对照组为77.50%(31/40),组间比较差异有统计学意义(χ2=5.165,P=0.023)。②治疗后观察组患者的骨密度(BMD)高于对照组,血清骨钙素(BGP)低于对照组,组间对比差异明显(t=4.308、4.807,P=0.000、0.000)。③观察组血清游离三碘甲状腺原氨酸(FT3)、血清游离甲状腺素(FT4)水平均低于对照组,而血清促甲状腺素(TSH)水平则高于对照组,组间差异明显(t=6.560、6.458、4.233,P=0.000、0.000、0.000)。④观察组不良反应发生率15.00%(6/40),对照组为10.00%(4/40),组间对比差异无统计学意义(χ~2=0.457,P=0.499)。结论瑞舒伐他汀联合阿仑膦酸钠治疗甲状腺功能亢进继发骨质疏松的疗效显著,能够改善患者的甲状腺功能、骨密度和血清骨钙素,值得临床推荐。
Objective To investigate the clinical efficacy of rosuvastatin combined with alendronate in the treatment of osteoporosis secondary to hyperthyroidism and its effect on bone mineral density and serum markers. Methods 80 patients with hyperthyroidism secondary to osteoporosis who were treated in our hospital from January 2016 to January 2018 were convenient enrolled. The patients were divided into observation group and control group according to the principle of random distribution, 40 cases each. The control group was treated with alendronate, and the patients in the observation group were treated with rosuvastatin. After 3 months of continuous treatment, the clinical efficacy, thyroid function index, bone mineral density and serum index, and incidence of adverse reactions were compared between the two groups. Results 1.The total effective rate of the observation group was 95.00%(38/40), and that of the control group was 77.50%(31/40). The difference between the groups was significant(χ2=5.165, P=0.023). 2.After treatment, the bone mineral density(BMD) of the observation group was higher than that of the control group, serum osteocalcin(BGP) was lower than the control group, and the difference between the groups was significant(t=4.308, 4.807, P=0.000, 0.000). 3.The levels of serum free triiodothyronine(FT3) and serum free thyroxine(FT4) in the observation group were lower than those in the control group, while the serum thyrotropin(TSH) level was higher than that in the control group(χ~2= 6.560, 6.458, 4.233, P=0.000, 0.000, 0.000). 4.The incidence of adverse reactions in the observation group was 15.00%(6/40), and that in the control group was 10.00%(4/40). There was no significant difference between the groups(χ~2=0.457, P=0.499). Conclusion Rosuvastatin combined with alendronate in the treatment of hyperthyroidism secondary to osteoporosis is effective in improving thyroid function, bone mineral density and serum osteocalcin. It is worthy of clinical recommendation.
Objective To investigate the clinical efficacy of rosuvastatin combined with alendronate in the treatment of osteoporosis secondary to hyperthyroidism and its effect on bone mineral density and serum markers. Methods 80 patients with hyperthyroidism secondary to osteoporosis who were treated in our hospital from January 2016 to January 2018 were convenient enrolled. The patients were divided into observation group and control group according to the principle of random distribution, 40 cases each. The control group was treated with alendronate, and the patients in the observation group were treated with rosuvastatin. After 3 months of continuous treatment, the clinical efficacy, thyroid function index, bone mineral density and serum index, and incidence of adverse reactions were compared between the two groups. Results 1.The total effective rate of the observation group was 95.00%(38/40), and that of the control group was 77.50%(31/40). The difference between the groups was significant(χ2=5.165, P=0.023). 2.After treatment, the bone mineral density(BMD) of the observation group was higher than that of the control group, serum osteocalcin(BGP) was lower than the control group, and the difference between the groups was significant(t=4.308, 4.807, P=0.000, 0.000). 3.The levels of serum free triiodothyronine(FT3) and serum free thyroxine(FT4) in the observation group were lower than those in the control group, while the serum thyrotropin(TSH) level was higher than that in the control group(χ~2= 6.560, 6.458, 4.233, P=0.000, 0.000, 0.000). 4.The incidence of adverse reactions in the observation group was 15.00%(6/40), and that in the control group was 10.00%(4/40). There was no significant difference between the groups(χ~2=0.457, P=0.499). Conclusion Rosuvastatin combined with alendronate in the treatment of hyperthyroidism secondary to osteoporosis is effective in improving thyroid function, bone mineral density and serum osteocalcin. It is worthy of clinical recommendation.
引文
[1]张煜,陈茂华,李坚,等.丹红联合瑞舒伐他汀治疗不稳定型心绞痛的临床疗效及对患者血清炎性因子和血液流变学指标的影响[J].山西医药杂志, 2017, 46(13):1554-1557.
[2]曹甜甜,张巍,张云,等.强心益气方联合瑞舒伐他汀治疗急性心肌梗死的疗效及对患者血清相关指标的影响[J].现代生物医学进展, 2017, 17(5):866-869.
[3]杨骁.瑞舒伐他汀联合甲状腺激素替代治疗对老年甲状腺机能减退症患者血脂、脂质过氧化和颈动脉硬化的影响[J].国际检验医学杂志, 2013, 34(2):151-152.
[4]韦建.瑞舒伐他汀钙对2型糖尿病伴骨质疏松症患者骨密度及颈动脉硬化斑块的影响[J].中国综合临床, 2017,33(8):167-169.
[5]钟方.唑来膦酸联合瑞舒伐他汀治疗老年糖尿病合并骨质疏松对患者骨代谢的影响[J].中外医疗, 2017,24(35):109-112.
[6]杨建军,庞小华,张建明,等.瑞舒伐他汀联合替罗非班对急性冠状动脉综合征并发糖尿病患者PCI术后血清炎症因子水平和肾功能的影响[J].中国药房, 2018,27(5):679-683.
[7]黄海涛,刘宏军,陈茂华,等.瑞舒伐他汀联合普罗布考对冠心病合并高胆固醇血症患者血脂代谢及血管内皮功能的影响[J].实用心脑肺血管病杂志, 2017,23(12):120-122.
[8]张潇,曾鼎华.普罗布考联合瑞舒伐他汀治疗血管性痴呆的临床观察[J].中国药房, 2017, 28(5):649-652.
[9]张儒,吴鹏.唑来膦酸联合瑞舒伐他汀辅助治疗老年骨质疏松性椎体压缩性骨折临床观察[J].中国骨质疏松杂志,2018,34(3):120-123.
[2]曹甜甜,张巍,张云,等.强心益气方联合瑞舒伐他汀治疗急性心肌梗死的疗效及对患者血清相关指标的影响[J].现代生物医学进展, 2017, 17(5):866-869.
[3]杨骁.瑞舒伐他汀联合甲状腺激素替代治疗对老年甲状腺机能减退症患者血脂、脂质过氧化和颈动脉硬化的影响[J].国际检验医学杂志, 2013, 34(2):151-152.
[4]韦建.瑞舒伐他汀钙对2型糖尿病伴骨质疏松症患者骨密度及颈动脉硬化斑块的影响[J].中国综合临床, 2017,33(8):167-169.
[5]钟方.唑来膦酸联合瑞舒伐他汀治疗老年糖尿病合并骨质疏松对患者骨代谢的影响[J].中外医疗, 2017,24(35):109-112.
[6]杨建军,庞小华,张建明,等.瑞舒伐他汀联合替罗非班对急性冠状动脉综合征并发糖尿病患者PCI术后血清炎症因子水平和肾功能的影响[J].中国药房, 2018,27(5):679-683.
[7]黄海涛,刘宏军,陈茂华,等.瑞舒伐他汀联合普罗布考对冠心病合并高胆固醇血症患者血脂代谢及血管内皮功能的影响[J].实用心脑肺血管病杂志, 2017,23(12):120-122.
[8]张潇,曾鼎华.普罗布考联合瑞舒伐他汀治疗血管性痴呆的临床观察[J].中国药房, 2017, 28(5):649-652.
[9]张儒,吴鹏.唑来膦酸联合瑞舒伐他汀辅助治疗老年骨质疏松性椎体压缩性骨折临床观察[J].中国骨质疏松杂志,2018,34(3):120-123.